Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-001 nasal powder formulations in healthy volunteers
NCT03198676Phase 1Completed
- Sponsor
- PrEP Biopharm
- Start
- May 2017
- Primary completion
- May 2017
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of polyinosine-polycytidylic acid in upper respiratory tract infection (URI) (4 arms), sponsored by PrEP Biopharm. Primary endpoint: Changes in baseline in nasal mucosal secretions and serum cytokine concentrations at 5 days. Started May 2017; status: completed.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
upper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT03198676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198676.